Congressional Hearing on LDTs: Split on FDA Regulation but Support for VALID
FDA Law Blog: Biosimilars
MARCH 31, 2024
Gibbs — On March 21, 2024, the House Energy and Commerce held a subcommittee hearing titled “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” Van Meter also testified that this is even more consequential for pediatric patients, small patient populations and patients with rare diseases.
Let's personalize your content